Regulatory lymphocytes: the dice that resolve the tumor endgame
Appl. cancer res
;
40: 1-9, Oct. 19, 2020. ilus
Article
in English
| LILACS, Inca
| ID: biblio-1281364
ABSTRACT
A large number of cancer patients relapse after chemotherapeutic treatment. The immune system is capable of identifying and destroying cancer cells, so recent studies have highlighted the growing importance of using combinatorial chemotherapy and immunotherapy. However, many patients have innate or acquired resistance to immunotherapies. Long-term follow-up in a pooled meta-analysis exhibited long-term survival in approximately 20% of patients treated with immune checkpoint inhibitors or the adoptive transfer of chimeric T cells. It has been reported that high levels of immunoregulatory cells in cancer patients contribute to immunotherapy resistance via immunosuppression. Among the most important regulatory cell subtypes are the CD4+ T-regulatory cells (Tregs), identified by their expression of the well-characterized, lineage-specific transcription factor FOXP3. In addition to CD4+ Tregs, other regulatory cells present in the tumor microenvironment, namely CD8+ Tregs and IL10-producing B-regulatory cells (Bregs) that also modulate the immune response in solid and lymphoid tumors. These cells together have detrimental effects on tumor immune surveillance and anti-tumor immunity. Therefore, targeting these regulatory lymphocytes will be crucial in improving treatment outcomes for immunotherapy.
Full text:
Available
Index:
LILACS (Americas)
Main subject:
T-Lymphocytes, Regulatory
/
Immunotherapy
/
Neoplasms
Type of study:
Prognostic study
Language:
English
Journal:
Appl. cancer res
Journal subject:
Neoplasms
Year:
2020
Type:
Article
Affiliation country:
India
Institution/Affiliation country:
Division of Molecular Medicine/IN
Similar
MEDLINE
...
LILACS
LIS